扶正抗癌方联合化疗治疗中晚期食管癌的临床疗效研究

目的探讨扶正抗癌方联合化疗治疗中晚期食管癌的临床效果。方法中晚期食管癌患者100例，按照随机数字表法分成两组，每组各50例，观察组患者采取扶正抗癌方联合化疗方案，对照组单纯采取化疗方案，分别连续治疗14d后，对比两组患者的治疗总有效率、BI评分、不良反应情况、以及满意度。结果采取扶正抗癌方联合化疗方案后，治疗总有效率达92．00％，明显优于常规治疗组的72.00％（P〈0．05）；观察组患者的日常生活活动量表评分（89．43±7．12）分，明显高于对照组（P〈0．05）；观察组患者中2例出现消化道不良反应，3例出现白细胞不良反应，总不良反应率显著低于常规治疗组（P〈0．05）；观察组治疗后CD4^＋和CD4^＋／CD8^＋水平较治疗前明显增加，且差异有统计学意义（P〈0．05）；治疗后两组比较，观察组CD4^＋和CD4^＋／CD8^＋水平明显高于对照组，差异有统计学意义（P〈0．05），观察组可明显提高患者的免疫功能，优于对照组。结论对中晚期食管癌患者采取扶正抗癌方联合化疗方案的应用效果显著，可明显改善患者的各项临床症状，改善患者预后与日常生活质量，提高免疫力，治疗方案安全可靠，值得在今后的临床工作中实践推广。

Objective Effect of Fu-zheng Anti-carcinoma Prescription with chemotherapy on the Esophagus cancer patients at middle and late stages was studied. Method 100 cases of locally advanced esophageal cancer patients were picked from May 2014 to May 2016 treated as the research object, according to the law of random numbers, they were divided into two groups, each group of 50 cases. Conventional group adopted the chemotherapy regimens, and experimental group patients adopted Fu-zheng Anti-carcinoma Prescription with chemotherapy, after 14d treatment, two groups of the treatment on patients with total effective rate, BI score, adverse reactions, and satisfaction were compared, respectively. Results Patients treated by the centralizer cancer after combined chemotherapy regimens, total effective rate of 92.00%, was better than the conventional treatment group （ P〈0.05 ） ; The experimental group patients daily life events scale score was （ 89.43 ± 7.12 ） significantly higher than normal group （ P〈0.05 ） .Experimental group only 2 cases with gastrointestinal adverse reactions in patients with leucocyte and 3 cases with adverse reactions, the total rate of adverse reactions was significantly lower than that of conventional treatment group （ P〈0.05 ） .The experimental group＇ s CD4^＋ and CD4^＋/CD8^＋ levels are significantly increased after treatment, and statistically significant （ P〈0.05 ） .Compared the two groups after treatment, the levels of CD4^＋ and CD4^＋/CD8^＋ in experimental group were significantly higher than that in conventional group, after statistics processing had significant difference （ P〈0.05 ） , the experimental group obviously improved the patient＇s immune function, and was superior to the conventional group. Conclusion Esophageal cancer patients in middle-late stage treated by Fu-zheng Anti-carcinoma Prescription with chemotherapy is remarkable. This is a safe and reliable treatment that can obviously improve the clinical symptoms and improve patients prognosis and quality of daily life, which is worth popularizing in the future clinical work practice.